Immunochemotherapy versus rituximab in anti-MAG neuropathy: a report of 64 patients

Monoclonal immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) neuropathy is a rare disabling condition, most commonly treated with rituximab monotherapy (R), which leads to neurological improvement in only 30%-50% of patients. The combination of rituximab plus chemotherapy has been pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2022-07, Vol.198 (2), p.298-306
Hauptverfasser: Nivet, Thomas, Baptiste, Amandine, Belin, Lisa, Dalbin, Pascale, Algrin, Caroline, Choquet, Sylvain, Lamy, Thierry, Morel, Véronique, Musset, Lucile, Roos- Weil, Damien, Viala, Karine, Leblond, Véronique, Baron, Marine
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 306
container_issue 2
container_start_page 298
container_title British journal of haematology
container_volume 198
creator Nivet, Thomas
Baptiste, Amandine
Belin, Lisa
Dalbin, Pascale
Algrin, Caroline
Choquet, Sylvain
Lamy, Thierry
Morel, Véronique
Musset, Lucile
Roos- Weil, Damien
Viala, Karine
Leblond, Véronique
Baron, Marine
description Monoclonal immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) neuropathy is a rare disabling condition, most commonly treated with rituximab monotherapy (R), which leads to neurological improvement in only 30%-50% of patients. The combination of rituximab plus chemotherapy has been proven to improve the level of responses. We studied the outcomes of anti-MAG neuropathy patients treated either by R, or by immunochemotherapy (ICT) in our centre, focusing on the incidence of the first neurological response evaluated by the modified Rankin Scale (mRS). From 2011 to 2018, 64 patients were studied: 34 were treated with R and 30 with ICT. According to our treatment decisionmaking process, the median mRS was higher in the ICT group (mRS 2) compared to the R group (mRS 1). At 1 year, mRS improvement rates were 46% and 18% of the ICT and R groups of patients respectively, with a median time to response of 8 and 13 months (p=0.023). Adverse effects were higher in the ICT group: 62% vs 15% (p˂0.01) all grades included. One secondary acute leukaemia occurred 5 years after treatment by ICT. In conclusion, ICT may be used as a valid option for patients with rapidly progressive and/or severe anti-MAG neuropathy symptoms.
doi_str_mv 10.1111/bjh.18202
format Article
fullrecord <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03643293v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_03643293v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_03643293v13</originalsourceid><addsrcrecordid>eNqVjMFKAzEURR-i2LHtwj94WxdT30syM9VdEbWCrux-SCUlKZ1kSDLF-XtH8Ac8mwuHywG4ZVrxxP3-aFe8FiQuoGBZV6VgxZdQEFFTMqn1DG5SOhKxpIqvYSYrJajhpoDPt64bfPiypgvZmqj7Ec8mpiFhdHn4dp3eo_OofXblx-YVvRli6HW24yNqjKYPMWM4YK1wss74nBZwddCnZJZ_O4e7l-fd07a0-tT2cUrGsQ3atdvNe_vrSNZKigd5Zvmf7w_YOEqu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Immunochemotherapy versus rituximab in anti-MAG neuropathy: a report of 64 patients</title><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><creator>Nivet, Thomas ; Baptiste, Amandine ; Belin, Lisa ; Dalbin, Pascale ; Algrin, Caroline ; Choquet, Sylvain ; Lamy, Thierry ; Morel, Véronique ; Musset, Lucile ; Roos- Weil, Damien ; Viala, Karine ; Leblond, Véronique ; Baron, Marine</creator><creatorcontrib>Nivet, Thomas ; Baptiste, Amandine ; Belin, Lisa ; Dalbin, Pascale ; Algrin, Caroline ; Choquet, Sylvain ; Lamy, Thierry ; Morel, Véronique ; Musset, Lucile ; Roos- Weil, Damien ; Viala, Karine ; Leblond, Véronique ; Baron, Marine</creatorcontrib><description>Monoclonal immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) neuropathy is a rare disabling condition, most commonly treated with rituximab monotherapy (R), which leads to neurological improvement in only 30%-50% of patients. The combination of rituximab plus chemotherapy has been proven to improve the level of responses. We studied the outcomes of anti-MAG neuropathy patients treated either by R, or by immunochemotherapy (ICT) in our centre, focusing on the incidence of the first neurological response evaluated by the modified Rankin Scale (mRS). From 2011 to 2018, 64 patients were studied: 34 were treated with R and 30 with ICT. According to our treatment decisionmaking process, the median mRS was higher in the ICT group (mRS 2) compared to the R group (mRS 1). At 1 year, mRS improvement rates were 46% and 18% of the ICT and R groups of patients respectively, with a median time to response of 8 and 13 months (p=0.023). Adverse effects were higher in the ICT group: 62% vs 15% (p˂0.01) all grades included. One secondary acute leukaemia occurred 5 years after treatment by ICT. In conclusion, ICT may be used as a valid option for patients with rapidly progressive and/or severe anti-MAG neuropathy symptoms.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18202</identifier><identifier>PMID: 35420717</identifier><language>eng</language><publisher>Wiley</publisher><subject>Hematology ; Human health and pathology ; Immunology ; Immunotherapy ; Life Sciences ; Neurons and Cognition</subject><ispartof>British journal of haematology, 2022-07, Vol.198 (2), p.298-306</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://hal.sorbonne-universite.fr/hal-03643293$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Nivet, Thomas</creatorcontrib><creatorcontrib>Baptiste, Amandine</creatorcontrib><creatorcontrib>Belin, Lisa</creatorcontrib><creatorcontrib>Dalbin, Pascale</creatorcontrib><creatorcontrib>Algrin, Caroline</creatorcontrib><creatorcontrib>Choquet, Sylvain</creatorcontrib><creatorcontrib>Lamy, Thierry</creatorcontrib><creatorcontrib>Morel, Véronique</creatorcontrib><creatorcontrib>Musset, Lucile</creatorcontrib><creatorcontrib>Roos- Weil, Damien</creatorcontrib><creatorcontrib>Viala, Karine</creatorcontrib><creatorcontrib>Leblond, Véronique</creatorcontrib><creatorcontrib>Baron, Marine</creatorcontrib><title>Immunochemotherapy versus rituximab in anti-MAG neuropathy: a report of 64 patients</title><title>British journal of haematology</title><description>Monoclonal immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) neuropathy is a rare disabling condition, most commonly treated with rituximab monotherapy (R), which leads to neurological improvement in only 30%-50% of patients. The combination of rituximab plus chemotherapy has been proven to improve the level of responses. We studied the outcomes of anti-MAG neuropathy patients treated either by R, or by immunochemotherapy (ICT) in our centre, focusing on the incidence of the first neurological response evaluated by the modified Rankin Scale (mRS). From 2011 to 2018, 64 patients were studied: 34 were treated with R and 30 with ICT. According to our treatment decisionmaking process, the median mRS was higher in the ICT group (mRS 2) compared to the R group (mRS 1). At 1 year, mRS improvement rates were 46% and 18% of the ICT and R groups of patients respectively, with a median time to response of 8 and 13 months (p=0.023). Adverse effects were higher in the ICT group: 62% vs 15% (p˂0.01) all grades included. One secondary acute leukaemia occurred 5 years after treatment by ICT. In conclusion, ICT may be used as a valid option for patients with rapidly progressive and/or severe anti-MAG neuropathy symptoms.</description><subject>Hematology</subject><subject>Human health and pathology</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Life Sciences</subject><subject>Neurons and Cognition</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqVjMFKAzEURR-i2LHtwj94WxdT30syM9VdEbWCrux-SCUlKZ1kSDLF-XtH8Ac8mwuHywG4ZVrxxP3-aFe8FiQuoGBZV6VgxZdQEFFTMqn1DG5SOhKxpIqvYSYrJajhpoDPt64bfPiypgvZmqj7Ec8mpiFhdHn4dp3eo_OofXblx-YVvRli6HW24yNqjKYPMWM4YK1wss74nBZwddCnZJZ_O4e7l-fd07a0-tT2cUrGsQ3atdvNe_vrSNZKigd5Zvmf7w_YOEqu</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Nivet, Thomas</creator><creator>Baptiste, Amandine</creator><creator>Belin, Lisa</creator><creator>Dalbin, Pascale</creator><creator>Algrin, Caroline</creator><creator>Choquet, Sylvain</creator><creator>Lamy, Thierry</creator><creator>Morel, Véronique</creator><creator>Musset, Lucile</creator><creator>Roos- Weil, Damien</creator><creator>Viala, Karine</creator><creator>Leblond, Véronique</creator><creator>Baron, Marine</creator><general>Wiley</general><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>202207</creationdate><title>Immunochemotherapy versus rituximab in anti-MAG neuropathy: a report of 64 patients</title><author>Nivet, Thomas ; Baptiste, Amandine ; Belin, Lisa ; Dalbin, Pascale ; Algrin, Caroline ; Choquet, Sylvain ; Lamy, Thierry ; Morel, Véronique ; Musset, Lucile ; Roos- Weil, Damien ; Viala, Karine ; Leblond, Véronique ; Baron, Marine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_03643293v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Hematology</topic><topic>Human health and pathology</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Life Sciences</topic><topic>Neurons and Cognition</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nivet, Thomas</creatorcontrib><creatorcontrib>Baptiste, Amandine</creatorcontrib><creatorcontrib>Belin, Lisa</creatorcontrib><creatorcontrib>Dalbin, Pascale</creatorcontrib><creatorcontrib>Algrin, Caroline</creatorcontrib><creatorcontrib>Choquet, Sylvain</creatorcontrib><creatorcontrib>Lamy, Thierry</creatorcontrib><creatorcontrib>Morel, Véronique</creatorcontrib><creatorcontrib>Musset, Lucile</creatorcontrib><creatorcontrib>Roos- Weil, Damien</creatorcontrib><creatorcontrib>Viala, Karine</creatorcontrib><creatorcontrib>Leblond, Véronique</creatorcontrib><creatorcontrib>Baron, Marine</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nivet, Thomas</au><au>Baptiste, Amandine</au><au>Belin, Lisa</au><au>Dalbin, Pascale</au><au>Algrin, Caroline</au><au>Choquet, Sylvain</au><au>Lamy, Thierry</au><au>Morel, Véronique</au><au>Musset, Lucile</au><au>Roos- Weil, Damien</au><au>Viala, Karine</au><au>Leblond, Véronique</au><au>Baron, Marine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunochemotherapy versus rituximab in anti-MAG neuropathy: a report of 64 patients</atitle><jtitle>British journal of haematology</jtitle><date>2022-07</date><risdate>2022</risdate><volume>198</volume><issue>2</issue><spage>298</spage><epage>306</epage><pages>298-306</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Monoclonal immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) neuropathy is a rare disabling condition, most commonly treated with rituximab monotherapy (R), which leads to neurological improvement in only 30%-50% of patients. The combination of rituximab plus chemotherapy has been proven to improve the level of responses. We studied the outcomes of anti-MAG neuropathy patients treated either by R, or by immunochemotherapy (ICT) in our centre, focusing on the incidence of the first neurological response evaluated by the modified Rankin Scale (mRS). From 2011 to 2018, 64 patients were studied: 34 were treated with R and 30 with ICT. According to our treatment decisionmaking process, the median mRS was higher in the ICT group (mRS 2) compared to the R group (mRS 1). At 1 year, mRS improvement rates were 46% and 18% of the ICT and R groups of patients respectively, with a median time to response of 8 and 13 months (p=0.023). Adverse effects were higher in the ICT group: 62% vs 15% (p˂0.01) all grades included. One secondary acute leukaemia occurred 5 years after treatment by ICT. In conclusion, ICT may be used as a valid option for patients with rapidly progressive and/or severe anti-MAG neuropathy symptoms.</abstract><pub>Wiley</pub><pmid>35420717</pmid><doi>10.1111/bjh.18202</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 2022-07, Vol.198 (2), p.298-306
issn 0007-1048
1365-2141
language eng
recordid cdi_hal_primary_oai_HAL_hal_03643293v1
source Access via Wiley Online Library; Wiley Online Library (Open Access Collection)
subjects Hematology
Human health and pathology
Immunology
Immunotherapy
Life Sciences
Neurons and Cognition
title Immunochemotherapy versus rituximab in anti-MAG neuropathy: a report of 64 patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A11%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunochemotherapy%20versus%20rituximab%20in%20anti-MAG%20neuropathy:%20a%20report%20of%2064%20patients&rft.jtitle=British%20journal%20of%20haematology&rft.au=Nivet,%20Thomas&rft.date=2022-07&rft.volume=198&rft.issue=2&rft.spage=298&rft.epage=306&rft.pages=298-306&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18202&rft_dat=%3Chal%3Eoai_HAL_hal_03643293v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35420717&rfr_iscdi=true